Form 4: Zoetis Executive Jamie Brannan Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Executive Vice President Jamie Brannan reports the acquisition of stock options and restricted stock units in Zoetis Inc.
Summary
- Jamie Brannan, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of 13,877 stock options with an exercise price of $156.64, and 3,562 restricted stock units (RSUs) on February 19, 2025.
- The RSUs will vest in three equal installments on the first, second, and third anniversaries of the grant date.
- The stock options also vest in three equal installments on the first, second, and third anniversaries of the grant date and expire ten years from the grant date.
- Brannan also holds previously granted RSUs and stock options with varying vesting schedules and exercise prices.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, indicating a stable and well-managed company. The sentiment is neutral to positive.
Positives
- The grant of stock options and RSUs aligns executive compensation with company performance and shareholder value.
- Vesting schedules incentivize continued service and commitment from the executive.
Future Outlook
The vesting schedules for the RSUs and stock options extend over the next three years, incentivizing continued service.
Industry Context
Stock option and RSU grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Zoetis's equity compensation practices are generally in line with those of its peers in the animal health industry, such as Elanco and Merck Animal Health.
- These companies also utilize stock options and restricted stock units as key components of executive compensation packages.
Stakeholder Impact
- The equity grants align executive interests with shareholder value.
- Employees may be motivated by the potential for similar equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| February 13, 2018 | 2,764 stock options granted at an exercise price of $73.24 per option. |
| February 12, 2019 | 1,465 stock options granted at an exercise price of $87.51 per option. |
| February 11, 2020 | 732 stock options granted at an exercise price of $144.03 per option. |
| February 10, 2021 | 869 stock options granted at an exercise price of $160.62 per option. |
| February 8, 2022 | 1,111 stock options granted at an exercise price of $201.30 per option. |
| February 8, 2023 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 6, 2024 | One-third of each RSU vests and is settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 19, 2025 | Date of the reported transaction: grant of stock options and RSUs. |
| February 19, 2025 | One-third of each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first, second and third anniversaries of the date of grant. |
| February 21, 2025 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.